在急性髓性白血病中,FLT3抑制剂会诱导p53的不稳定性,由STAT5/MDM2/p53的竞争性相互作用驱动
Han Zhong Pei1, Yao Guo1, Yuming Zhao1
1Pediatric Hematology Laboratory, Division of Hematology/Oncology, Department of Pediatrics, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, Guangdong, China.
Cancer letters
|January 5, 2025
概括
在急性髓性白血病 (AML) 中,FLT3抑制剂通过阻断STAT5.5导致p53降解. 将MDM2抑制剂与FLT3抑制剂结合起来,可以增强抗白血病效果,克服抗药性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 血液学 血液学 血液学
背景情况:
- FLT3突变在急性髓性白血病 (AML) 中很常见,是治疗点.
- FLT3 抑制剂显示有效性,但由于药物耐药性机制而面临挑战.
研究的目的:
- 阐明AML中FLT3抑制剂耐药性的机制.
- 确定结合FLT3和MDM2抑制剂用于AML治疗的新型治疗策略.
主要方法:
- 研究了STAT5,MDM2和p53相互作用在FLT3抑制剂反应中的作用.
- 利用基于细胞的测定和AML的体内小鼠模型.
- 评估了同时使用FLT3和MDM2抑制剂的影响.
主要成果:
- 通过阻断STAT5核转位,FLT3抑制剂通过无化诱导p53降解.
- 在调节p53稳定性和MDM2结合方面,STAT5起着至关重要的作用.
- 同时使用MDM2抑制剂与FLT3抑制剂增强了apoptosis,并在体内抑制了白血病.
结论:
- FLT3 抑制剂通过一个依赖于 STAT5 的机制促进p53 降解,从而促进耐药性.
- 与MDM2抑制剂的联合治疗提供了一个有前途的策略,以克服AML中的FLT3抑制剂耐药性.
相关概念视频
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
Drugs that Destabilize Microtubules
1.9K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K
Destabilization of Microtubules
2.6K
The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
2.6K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Microtubule Instability
5.0K
Microtubules are hollow cylindrical filaments having a diameter of approximately 25 nm and a length that varies from 200 nm to 25 μm. GTP-bound tubulin subunits form αβ-heterodimers for microtubule assembly. These core building blocks interact longitudinally, polymerizing into protofilaments. The protofilaments then interact with one another through lateral bonding forces to form stable cylindrical microtubules. These cylindrical filaments are dynamic as they undergo repeated...
5.0K


